Latest Healthcare News

Anatara Lifesciences has received nearly $1 million from the Australian Government’s R&D tax incentive, providing a vital capital injection to advance its Anti-Obesity pre-clinical studies.

PainChek Limited has raised A$7.5 million through a strongly supported placement to accelerate its US market entry following anticipated FDA clearance and expand its innovative AI pain assessment technology internationally.

Compumedics has secured two significant four-year distribution agreements in China worth A$24.4 million, reinforcing its strategic foothold in Asia with committed annual growth of at least 10%.

Emyria has secured a landmark multi-year funding agreement with Medibank to reimburse PTSD patients under its Empax program, alongside opening a second clinic and reporting durable clinical improvements in treatment-resistant PTSD cases.

Clarity Pharmaceuticals has completed a $203 million institutional placement at a premium, bolstering its cash reserves to nearly $288 million and positioning the company to advance pivotal clinical trials and commercial preparations for its cancer-fighting radiopharmaceuticals.

ECS Botanics reports a 20% quarterly surge in direct-to-consumer sales and a record medicinal cannabis harvest, supported by an expanded loan facility to fuel further growth.

Botanix Pharmaceuticals reports a strong commercial ramp-up for Sofdra™, with net revenue jumping from $0.7 million to $4.3 million in one quarter, supported by a $40 million capital raise and a $30 million debt facility.

Artrya has launched its AI-powered Salix Coronary Anatomy platform in the U.S. and submitted its Coronary Plaque module for FDA clearance, marking a key step in its commercial expansion. A new five-year contract with Tanner Health signals the start of U.S. revenues.

Proteomics International Laboratories has secured $12 million to fast-track its precision diagnostic tests, including the US launch of PromarkerD for diabetic kidney disease, backed by a new AMA billing code. The company also advances its pipeline with new patents and commercial partnerships.

Global Health Limited reported a robust June quarter with a 65% rise in annual sales and a strategic pivot towards AI-driven efficiencies, aiming for profitability by mid-2026.

Radiopharm Theranostics has received FDA clearance to begin a Phase I clinical trial for RV-01, a novel radiopharmaceutical targeting the 4Ig isoform of B7-H3 in solid tumors, marking a significant step forward in cancer treatment innovation.

Imricor Medical Systems reported significant regulatory and commercial progress in Q2 CY25, including CE mark approvals and expanded clinical trials, while maintaining a strong cash position.